AICDA (Q9GZX7) variants and mutations
AICDA (also known as Q9GZX7) is a human protein-coding gene encoding a single-stranded DNA cytosine deaminase protein. It initiates somatic hypermutation and class-switch recombination in activated B cells by deaminating cytosines in immunoglobulin genes. Biallelic loss-of-function variants cause hyper-IgM syndrome type 2, with impaired antibody diversification and recurrent infections. This analysis covers 504 AICDA variants and mutations. Of these, 89% have computational variant effect predictions. Disease context includes hyper-IgM syndrome type 2, hereditary disease, and B-cell chronic lymphocytic leukemia. Example AICDA variants include D2G, D2N, and S3S.
Variant analysis overview
- Gene: AICDA
- Protein: Q9GZX7
- UniProt accession: Q9GZX7
- Organism: Homo sapiens
- Variants analyzed: 504
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 291 unspecified-consequence records; 1 stop lost; 85 missense variants; 99 synonymous variants; 17 frameshift variants; 4 stop-gained variants; 4 splice-region variants; 2 in-frame deletions; 1 substitution
- Prediction scores: 447 variants have prediction scores (89% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: hyper-IgM syndrome type 2, hereditary disease, B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma, acute lymphoblastic leukemia, cancer, infection, myeloid sarcoma, lymphoma, Alzheimer disease, rheumatoid arthritis, gastric cancer.
Protein structure and variant hotspots
- Protein features: 1 domains; 3 binding sites; 2 post-translational modification sites.
- Structural context: 277 variants have structural context.
- PTM context: 3 variants overlap post-translational modification sites.
- Experimental data: 11 protein positions have experimental scores. Source: Deaminase activity of AID in generation 3, Deaminase activity of AID in generation 2, Deaminase activity of AID in generation 1.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable AICDA variants
Examples include D2G, D2N, S3S, L5M, L5L, M6T, M6V, N7K. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- D2G (p.Asp2Gly), TOPMed rs1941387220, MetaLR 0.21, MetaSVM -0.84
- D2N (p.Asp2Asn), ExAC rs768337561, gnomAD rs768337561, REVEL 0.12, MetaLR 0.20
- S3S (p.Ser3Ser), gnomAD 12-8607012-G-A, CADD 17.10
- L5M (p.Leu5Met), rs2136433390, ClinGen CA384038529, ClinVar RCV002859699, Uncertain significance, Inborn genetic diseases
- L5L (p.Leu5Leu), rs1484825115, gnomAD 12-8607006-C-T, CADD 9.64
- M6T (p.Met6Thr), TOPMed rs1447826810, gnomAD rs1447826810, REVEL 0.36, MetaLR 0.38
- M6V (p.Met6Val), gnomAD 12-8607005-T-C, REVEL 0.20, MetaLR 0.35
- N7K (p.Asn7Lys), rs901889062, ClinGen CA232301106, cosmic curated COSV57566, ClinVar RCV001372775, REVEL 0.11, MetaLR 0.02, Uncertain significance, Hyper-IgM syndrome type 2
- R8G (p.Arg8Gly), ExAC rs763540826, TOPMed rs763540826, gnomAD rs763540826, Uncertain significance
- R8Q (p.Arg8Gln), rs773903008, ClinGen CA6434522, ClinVar RCV001883196, ExAC rs773903008, REVEL 0.21, MetaLR 0.07, Uncertain significance, Hyper-IgM syndrome type 2
- R8W (p.Arg8Trp), rs763540826, ClinGen CA6434523, cosmic curated COSV57564, ClinVar RCV001214840, REVEL 0.29, MetaLR 0.23, Uncertain significance, Hyper-IgM syndrome type 2
- R8R (p.Arg8Arg), rs104894985, gnomAD 12-8606997-C-A, CADD 3.47
- R9K (p.Arg9Lys), 1000Genomes rs751448269, REVEL 0.20, MetaLR 0.05
- R9R (p.Arg9Arg), gnomAD 12-8606994-C-T, CADD 6.52
- R9G (p.Arg9Gly), gnomAD 12-8606996-TC-T, CADD 16.20
- K10N (p.Lys10Asn), NCI-TCGA TCGA novel, MetaLR 0.21, MetaSVM -0.80, Variant assessed as somatic; moderate impact.
- K10R (p.Lys10Arg), rs768249578, ClinGen CA6434521, ClinVar RCV000307490, ExAC rs768249578, REVEL 0.11, MetaLR 0.23, Uncertain significance, Hyper-IgM syndrome type 2
- K10E (p.Lys10Glu), rs768249578, Uncertain significance
- F11F (p.Phe11Phe), rs1265796478, gnomAD 12-8606988-A-G, CADD 7.57
- F11L (p.Phe11Leu), gnomAD 12-8606990-A-G, REVEL 0.90, MetaLR 0.76
- Y13* (p.Tyr13Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- Y13Y (p.Tyr13Tyr), gnomAD 12-8606982-G-A, CADD 5.82
- Y13H (p.Tyr13His), gnomAD 12-8606984-A-G, REVEL 0.58, MetaLR 0.42
- Q14P (p.Gln14Pro), Ensembl rs761103470, REVEL 0.36, MetaLR 0.24
- F15L (p.Phe15Leu), rs2136433362, ClinGen CA384038374, ClinVar RCV001992299, UniProt VAR 077563, REVEL 0.71, MetaLR 0.49, Likely pathogenic, Hyper-IgM syndrome type 2
- K16Q (p.Lys16Gln), Ensembl rs1565510337, REVEL 0.63, MetaLR 0.63
- K16K (p.Lys16Lys), rs186739900, gnomAD 12-8606973-T-C, CADD 10.50
- N17M (p.Asn17Met), NCI-TCGA TCGA novel, MetaLR 0.76, MetaSVM 0.74, Variant assessed as somatic; high impact.
- N17N (p.Asn17Asn), rs749195364, gnomAD 12-8606970-A-G, CADD 5.25
- V18V (p.Val18Val), gnomAD 12-8606967-G-T, CADD 8.96
- R19C (p.Arg19Cys), NCI-TCGA Cosmic COSV5756, cosmic curated COSV57564, TOPMed rs1941296567, REVEL 0.59, MetaLR 0.48, Variant assessed as somatic; moderate impact.
- R19H (p.Arg19His), cosmic curated COSV99984, TOPMed rs1207955037, gnomAD rs1207955037, REVEL 0.48, MetaLR 0.48
- R19P (p.Arg19Pro), gnomAD 12-8606965-C-G, REVEL 0.51, MetaLR 0.38
- W20* (p.Trp20Ter), gnomAD rs1295238933, CADD 37.00
- W20C (p.Trp20Cys), NCI-TCGA TCGA novel, MetaLR 0.25, MetaSVM -0.65, Variant assessed as somatic; moderate impact.
- W20R (p.Trp20Arg), ExAC rs771765053, TOPMed rs771765053, gnomAD rs771765053, REVEL 0.61, MetaLR 0.25
- W20L (p.Trp20Leu), gnomAD 12-8606962-C-A, REVEL 0.47, MetaLR 0.35
- K22E (p.Lys22Glu), gnomAD rs1213198392, REVEL 0.24, MetaLR 0.22
- G23R (p.Gly23Arg), NCI-TCGA TCGA novel, REVEL 0.71, MetaLR 0.33, Variant assessed as somatic; moderate impact.
- G23G (p.Gly23Gly), gnomAD 12-8606952-A-G, CADD 3.87
- R24Q (p.Arg24Gln), rs886923939, ClinGen CA232301103, ClinVar RCV001070577, TOPMed rs886923939, REVEL 0.63, MetaLR 0.54, Likely pathogenic, Hyper-IgM syndrome type 2
- R24W (p.Arg24Trp), rs104894324, ClinGen CA117266, cosmic curated COSV57564, ClinVar RCV000005429, REVEL 0.87, MetaLR 0.58, Pathogenic, Hyper-IgM syndrome type 2
- R25C (p.Arg25Cys), rs1404944797, ClinGen CA384038220, ClinVar RCV003506282, UniProt VAR 014091, REVEL 0.21, MetaLR 0.27, Uncertain significance, Hyper-IgM syndrome type 2
- R25H (p.Arg25His), rs61730095, ClinGen CA6434517, cosmic curated COSV57563, ClinVar RCV000639379, REVEL 0.10, MetaLR 0.01, Benign/Likely benign, not specified; Hyper-IgM syndrome type 2; not provided
- R25R (p.Arg25Arg), gnomAD 12-8606946-A-C, CADD 3.73
- E26A (p.Glu26Ala), ExAC rs778768248, gnomAD rs778768248, REVEL 0.65, MetaLR 0.46
- E26K (p.Glu26Lys), cosmic curated COSV10506, NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- T27T (p.Thr27Thr), rs1431211104, gnomAD 12-8606940-G-C, CADD 10.10
- T27I (p.Thr27Ile), gnomAD 12-8606941-G-A, REVEL 0.94, MetaLR 0.75
- Y28H (p.Tyr28His), rs199697153, ClinGen CA6434515, ClinVar RCV001991407, 1000Genomes rs199697153, REVEL 0.79, MetaLR 0.54, Uncertain significance, Hyper-IgM syndrome type 2
- Y28N (p.Tyr28Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L29R (p.Leu29Arg), NCI-TCGA Cosmic COSV5756, cosmic curated COSV57566, REVEL 0.96, MetaLR 0.77, Variant assessed as somatic; moderate impact.
- L29L (p.Leu29Leu), rs753755859, gnomAD 12-8606934-C-T, CADD 10.50
- Y31* (p.Tyr31Ter), rs777729620, ClinGen CA384038123, ClinVar RCV003037444, Pathogenic, in HIGM2
- Y31C (p.Tyr31Cys), rs1057519097, ClinGen CA16043732, ClinVar RCV000415972, Ensembl rs1057519097, Likely pathogenic, not provided; Hyper-IgM syndrome type 2
- Y31H (p.Tyr31His), UniProt VAR 077564, Pathogenic, in HIGM2
- Y31Y (p.Tyr31Tyr), rs777729620, gnomAD 12-8606928-G-A, CADD 0.04
- V32A (p.Val32Ala), NCI-TCGA Cosmic COSV9998, cosmic curated COSV99984, REVEL 0.31, MetaLR 0.25, Variant assessed as somatic; moderate impact.
- V32I (p.Val32Ile), rs756147874, ClinGen CA6434512, ClinVar RCV002794783, ExAC rs756147874, REVEL 0.09, MetaLR 0.13, Uncertain significance, Hyper-IgM syndrome type 2
- V32L (p.Val32Leu), ExAC rs756147874, TOPMed rs756147874, gnomAD rs756147874, Uncertain significance
- V33V (p.Val33Val), rs752796959, gnomAD 12-8606922-C-T, CADD 7.50
- K34K (p.Lys34Lys), rs1941295506, gnomAD 12-8606919-C-T, CADD 7.20
- R35K (p.Arg35Lys), gnomAD rs1490176772, REVEL 0.49, MetaLR 0.53
- R35W (p.Arg35Trp), NCI-TCGA Cosmic COSV5756, cosmic curated COSV57565, MetaLR 0.45, MetaSVM -0.39, Variant assessed as somatic; moderate impact.
- R35R (p.Arg35Arg), rs1266809493, gnomAD 12-8606916-C-T, CADD 5.76
- R36C (p.Arg36Cys), rs200228627, ClinGen CA6434510, cosmic curated COSV99984, ClinVar RCV001865201, REVEL 0.58, MetaLR 0.45, Uncertain significance, Hyper-IgM syndrome type 2
- R36H (p.Arg36His), rs759799595, NCI-TCGA Cosmic COSV5756, cosmic curated COSV57563, 1000Genomes rs759799595, REVEL 0.33, MetaLR 0.32, Variant assessed as somatic; moderate impact.
- R36L (p.Arg36Leu), gnomAD 12-8606914-C-A, REVEL 0.40, MetaLR 0.20
- p.Asp37 Ser38del, rs1181609421, gnomAD 12-8606905-GCACTG, CADD 15.50
- D37D (p.Asp37Asp), gnomAD 12-8606910-G-A, CADD 1.39
- D37* (p.Asp37Ter), rs762778537, gnomAD 12-8606912-C-CA, CADD 24.30
- S38G (p.Ser38Gly), ESP rs377213745, ExAC rs377213745, gnomAD rs377213745, REVEL 0.11, MetaLR 0.13, Uncertain significance, Hyper-IgM syndrome type 2
- A39T (p.Ala39Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A39V (p.Ala39Val), ExAC rs766741360, REVEL 0.23, MetaLR 0.25
- A39A (p.Ala39Ala), gnomAD 12-8606904-A-C, CADD 8.17
- T40S (p.Thr40Ser), ExAC rs763449075, gnomAD rs763449075, MetaLR 0.36, MetaSVM -0.25
- T40K (p.Thr40Lys), gnomAD 12-8606902-G-T, REVEL 0.26, MetaLR 0.30
- S41S (p.Ser41Ser), rs1314298055, gnomAD 12-8606898-G-A, CADD 9.40
- S41F (p.Ser41Phe), gnomAD 12-8606899-G-A, REVEL 0.34, MetaLR 0.46
- S41T (p.Ser41Thr), gnomAD 12-8606900-A-T, REVEL 0.19, MetaLR 0.16
- S43L (p.Ser43Leu), rs2540253190, ClinGen CA384038009, ClinVar RCV002943081, Uncertain significance, Hyper-IgM syndrome type 2
- S43T (p.Ser43Thr), rs1941294885, ClinGen CA384038014, ClinVar RCV001294356, Ensembl rs1941294885, Uncertain significance, Hyper-IgM syndrome type 2
- S43S (p.Ser43Ser), gnomAD 12-8606892-T-G, CADD 2.37
- D45N (p.Asp45Asn), rs2540253177, ClinGen CA384038003, ClinVar RCV002943076, REVEL 0.34, MetaLR 0.38, Uncertain significance, Hyper-IgM syndrome type 2
- D45D (p.Asp45Asp), gnomAD 12-8606886-G-A, CADD 8.25
- D45T (p.Asp45Thr), gnomAD 12-8606887-TC-T, CADD 28.50
- F46L (p.Phe46Leu), ESP rs373878983, ExAC rs373878983, gnomAD rs373878983, REVEL 0.45, MetaLR 0.29
- G47V (p.Gly47Val), gnomAD 12-8606881-C-A, REVEL 0.90, MetaLR 0.44
- Y48C (p.Tyr48Cys), gnomAD rs1445777535, REVEL 0.28, MetaLR 0.26
- L49F (p.Leu49Phe), NCI-TCGA Cosmic COSV5756, NCI-TCGA Cosmic COSV9998, Variant assessed as somatic; moderate impact.
- L49I (p.Leu49Ile), NCI-TCGA Cosmic COSV5756, NCI-TCGA Cosmic COSV9998, cosmic curated COSV99984, Variant assessed as somatic; moderate impact.
- R50C (p.Arg50Cys), rs370700027, ClinGen CA6434502, cosmic curated COSV99984, ClinVar RCV000817790, REVEL 0.64, MetaLR 0.44, Uncertain significance, Inborn genetic diseases; Hyper-IgM syndrome type 2
- R50G (p.Arg50Gly), ESP rs370700027, ExAC rs370700027, TOPMed rs370700027, gnomAD rs370700027, Uncertain significance
- R50H (p.Arg50His), rs775067086, ExAC rs775067086, TOPMed rs775067086, gnomAD rs775067086, REVEL 0.46, MetaLR 0.44, Variant assessed as somatic; moderate impact.
- R50R (p.Arg50Arg), rs376807304, gnomAD 12-8606871-G-T, CADD 7.04
- R50L (p.Arg50Leu), gnomAD 12-8606872-C-A, REVEL 0.59, MetaLR 0.43
- K52E (p.Lys52Glu), TOPMed rs1941294465, gnomAD rs1941294465, REVEL 0.09, MetaLR 0.18
- K52K (p.Lys52Lys), rs374147134, gnomAD 12-8606865-C-T, CADD 29.60
- K52N (p.Lys52Asn), gnomAD 12-8606865-C-G, REVEL 0.17, MetaLR 0.36
- N53=, NCI-TCGA Cosmic COSV5756, Variant assessed as somatic; low impact.
- N53N (p.Asn53Asn), rs1941271782, gnomAD 12-8605483-G-A, CADD 0.01
- N53I (p.Asn53Ile), gnomAD 12-8605484-T-A, REVEL 0.17, MetaLR 0.15
- G54R (p.Gly54Arg), rs1565509771, ClinGen CA383819524, ClinVar RCV000695875, ClinVar RCV001091143, Uncertain significance, not provided; Hyper-IgM syndrome type 2
- G54S (p.Gly54Ser), NCI-TCGA Cosmic COSV5756, cosmic curated COSV57563, Uncertain significance, Hyper-IgM syndrome type 2
- C55C (p.Cys55Cys), gnomAD 12-8605477-G-A, CADD 8.70
- H56Y (p.His56Tyr), UniProt VAR 077565, REVEL 0.95, MetaLR 0.95, Uncertain significance, in HIGM2
- H56Q (p.His56Gln), gnomAD 12-8605474-G-GT, CADD 32.00
- H56R (p.His56Arg), gnomAD 12-8605475-T-C, REVEL 0.96, MetaLR 0.55
- V57A (p.Val57Ala), ExAC rs770592785, TOPMed rs770592785, gnomAD rs770592785, REVEL 0.17, MetaLR 0.07, Uncertain significance, Hyper-IgM syndrome type 2
- V57M (p.Val57Met), rs786205474, ClinGen CA235862, cosmic curated COSV57564, ClinVar RCV000171206, REVEL 0.40, MetaLR 0.45, Pathogenic/Likely pathogenic, Hyper-IgM syndrome type 2
- E58K (p.Glu58Lys), TOPMed rs1040748925
- E58E (p.Glu58Glu), gnomAD 12-8605468-T-C, CADD 5.77
- L59L (p.Leu59Leu), rs1363275730, gnomAD 12-8605467-A-G, CADD 1.37
- L60F (p.Leu60Phe), rs1941271183, ClinGen CA383819456, ClinVar RCV002944311, TOPMed rs1941271183, Uncertain significance, Hyper-IgM syndrome type 2
- L60P (p.Leu60Pro), gnomAD rs1179788630
- L60V (p.Leu60Val), TOPMed rs1941271183, REVEL 0.12, MetaLR 0.16, Uncertain significance
- L60L (p.Leu60Leu), rs749026925, gnomAD 12-8605462-G-T, CADD 7.96
- F61L (p.Phe61Leu), rs2540251869, ClinGen CA383819447, ClinVar RCV002295005, Uncertain significance, Hyper-IgM syndrome type 2
- F61F (p.Phe61Phe), rs772998186, gnomAD 12-8605459-G-A, CADD 12.70
- L62L (p.Leu62Leu), gnomAD 12-8605456-G-C, CADD 5.29
- R63C (p.Arg63Cys), ExAC rs753194739, gnomAD rs753194739, REVEL 0.41, MetaLR 0.35
- R63H (p.Arg63His), cosmic curated COSV57563, ESP rs368910905, ExAC rs368910905, TOPMed rs368910905, REVEL 0.20, MetaLR 0.16
- R63R (p.Arg63Arg), rs376176415, gnomAD 12-8605453-G-C, CADD 10.70
- R63S (p.Arg63Ser), gnomAD 12-8605455-G-T, REVEL 0.22, MetaLR 0.12
- Y64C (p.Tyr64Cys), TOPMed rs1350627350, gnomAD rs1350627350, REVEL 0.36, MetaLR 0.29, Uncertain significance, Hyper-IgM syndrome type 2
- Y64H (p.Tyr64His), rs944982893, ClinGen CA232648035, cosmic curated COSV10874, ClinVar RCV001965291, REVEL 0.09, MetaLR 0.14, Uncertain significance, Hyper-IgM syndrome type 2
- I65T (p.Ile65Thr), gnomAD 12-8605447-GA-G, CADD 29.20
- I65I (p.Ile65Ile), rs371803016, gnomAD 12-8605447-G-A, CADD 10.00
- S66L (p.Ser66Leu), rs1941270570, ClinGen CA383819373, NCI-TCGA Cosmic COSV5756, cosmic curated COSV57563, REVEL 0.36, MetaLR 0.12, Uncertain significance, Hyper-IgM syndrome type 2
- S66T (p.Ser66Thr), gnomAD rs1236265469, REVEL 0.17, MetaLR 0.13
- S66S (p.Ser66Ser), gnomAD 12-8605444-C-A, CADD 3.45
- D67E (p.Asp67Glu), rs2540251824, ClinGen CA383819360, ClinVar RCV003057290, Uncertain significance, Hyper-IgM syndrome type 2
- D67Y (p.Asp67Tyr), NCI-TCGA TCGA novel, REVEL 0.31, MetaLR 0.13, Variant assessed as somatic; moderate impact.
- W68* (p.Trp68Ter), rs104894325, ClinGen CA117268, ClinVar RCV000005430, ClinVar RCV003389747, CADD 38.00, Pathogenic
- W68L (p.Trp68Leu), 1000Genomes rs104894325, MetaLR 0.28, MetaSVM -0.65, Pathogenic
- W68S (p.Trp68Ser), gnomAD 12-8605439-C-G, REVEL 0.27, MetaLR 0.44
- D69A (p.Asp69Ala), gnomAD rs1361067041, MetaLR 0.05, MetaSVM -1.02
- D69E (p.Asp69Glu), TOPMed rs1047903541, gnomAD rs1047903541, REVEL 0.05, MetaLR 0.04
- D69V (p.Asp69Val), gnomAD rs1361067041, REVEL 0.26, MetaLR 0.05
- D69D (p.Asp69Asp), rs1047903541, gnomAD 12-8605435-G-A, CADD 7.43
- L70V (p.Leu70Val), rs929345572, ClinGen CA383819325, ClinVar RCV001922056, TOPMed rs929345572, REVEL 0.38, MetaLR 0.34, Uncertain significance, Hyper-IgM syndrome type 2
- L70L (p.Leu70Leu), rs104894984, gnomAD 12-8605432-T-C, CADD 9.13
- D71A (p.Asp71Ala), TOPMed rs973522609, gnomAD rs973522609, MetaLR 0.40, MetaSVM -0.23
- D71E (p.Asp71Glu), NCI-TCGA Cosmic COSV5756, cosmic curated COSV57564, REVEL 0.27, MetaLR 0.32, Variant assessed as somatic; moderate impact.
- D71G (p.Asp71Gly), TOPMed rs973522609, gnomAD rs973522609, REVEL 0.39, MetaLR 0.35
- D71H (p.Asp71His), TOPMed rs1344096355, gnomAD rs1344096355, REVEL 0.44, MetaLR 0.23
- D71D (p.Asp71Asp), rs773568521, gnomAD 12-8605429-G-A, CADD 9.73
- P72P (p.Pro72Pro), gnomAD 12-8605426-A-G, CADD 0.73
- P72A (p.Pro72Ala), gnomAD 12-8605428-G-C, REVEL 0.47, MetaLR 0.43
- G73D (p.Gly73Asp), rs750738642, ClinGen CA6434470, cosmic curated COSV57564, ClinVar RCV003494382, REVEL 0.14, MetaLR 0.11, Uncertain significance, not specified
- G73G (p.Gly73Gly), rs765686661, gnomAD 12-8605423-G-A, CADD 8.78
- R74C (p.Arg74Cys), rs1462302054, ClinGen CA383819270, ClinVar RCV003614493, gnomAD rs1462302054, REVEL 0.46, MetaLR 0.34, Uncertain significance, Hyper-IgM syndrome type 2
- R74H (p.Arg74His), NCI-TCGA Cosmic COSV5756, cosmic curated COSV57563, REVEL 0.20, MetaLR 0.23, Variant assessed as somatic; moderate impact.
- R74R (p.Arg74Arg), gnomAD 12-8605420-G-C, CADD 1.43
- R74P (p.Arg74Pro), gnomAD 12-8605421-C-G, REVEL 0.41, MetaLR 0.35
- R74L (p.Arg74Leu), gnomAD 12-8605421-C-A, REVEL 0.14, MetaLR 0.15
- C75R (p.Cys75Arg), Ensembl rs1327317645
- C75C (p.Cys75Cys), rs1156835358, gnomAD 12-8605417-G-A, CADD 11.00
- C75G (p.Cys75Gly), gnomAD 12-8605419-A-C, REVEL 0.30, MetaLR 0.19
- Y76Y (p.Tyr76Tyr), rs1426632550, gnomAD 12-8605414-G-A, CADD 8.91
- Y76C (p.Tyr76Cys), gnomAD 12-8605415-T-C, REVEL 0.74, MetaLR 0.41
- Y76H (p.Tyr76His), gnomAD 12-8605416-A-G, REVEL 0.83, MetaLR 0.56
- R77C (p.Arg77Cys), cosmic curated COSV10506, ExAC rs757613881, gnomAD rs757613881, REVEL 0.42, MetaLR 0.39
- R77G (p.Arg77Gly), NCI-TCGA Cosmic COSV9998, cosmic curated COSV99983, Variant assessed as somatic; moderate impact.
- R77H (p.Arg77His), rs1941269563, ClinGen CA383819226, NCI-TCGA Cosmic COSV5756, cosmic curated COSV57564, REVEL 0.41, MetaLR 0.31, Uncertain significance, Hyper-IgM syndrome type 2
- R77R (p.Arg77Arg), rs754343795, gnomAD 12-8605411-G-A, CADD 1.29
- V78A (p.Val78Ala), ExAC rs764543443, gnomAD rs764543443, REVEL 0.62, MetaLR 0.35
- V78I (p.Val78Ile), NCI-TCGA Cosmic COSV5756, cosmic curated COSV57563, REVEL 0.06, MetaLR 0.09, Variant assessed as somatic; moderate impact.
- V78L (p.Val78Leu), rs2540251710, ClinGen CA383819220, ClinVar RCV002926822, Uncertain significance, Hyper-IgM syndrome type 2
- T79I (p.Thr79Ile), cosmic curated COSV99984, ExAC rs759039199, TOPMed rs759039199, gnomAD rs759039199, REVEL 0.79, MetaLR 0.49
- T79P (p.Thr79Pro), Ensembl rs1591744459, REVEL 0.90, MetaLR 0.62
- T79S (p.Thr79Ser), ExAC rs759039199, TOPMed rs759039199, gnomAD rs759039199, MetaLR 0.59, MetaSVM 0.38
- W80* (p.Trp80Ter), TOPMed rs980830254, gnomAD rs980830254, CADD 39.00
- W80C (p.Trp80Cys), NCI-TCGA Cosmic COSV5756, cosmic curated COSV57563, Variant assessed as somatic; moderate impact., in HIGM2
- W80R (p.Trp80Arg), rs104894320, ClinGen CA117271, ClinVar RCV000005431, UniProt VAR 013775, Uncertain significance, Hyper-IgM syndrome type 2
- F81F (p.Phe81Phe), gnomAD 12-8605399-G-A, CADD 11.70
- T82P (p.Thr82Pro), Ensembl rs1591744449
- T82A (p.Thr82Ala), gnomAD 12-8605398-T-C, REVEL 0.20, MetaLR 0.25
- S83P (p.Ser83Pro), TOPMed rs1565509682, gnomAD rs1565509682, REVEL 0.81, MetaLR 0.57
- S83Y (p.Ser83Tyr), gnomAD 12-8605394-G-T, REVEL 0.83, MetaLR 0.59
Public AICDA analysis runs
- AICDA analysis run — AICDA (504 variants) — completed 2026-08-20